

Liisa Volin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7052321/publications.pdf>

Version: 2024-02-01

98
papers

2,377
citations

249298

26
h-index

242451

47
g-index

98
all docs

98
docs citations

98
times ranked

3243
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Leukemia</i> , 2021, 35, 2232-2242.	3.3	6
2	Long-term outcome after allogeneic stem cell transplantation in multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 1553-1567.	0.8	6
3	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021, 195, 417-428.	1.2	9
4	Meta-Analysis of Genome-Wide Association and Gene Expression Studies Implicates Donor T Cell Function and Cytokine Pathways in Acute GvHD. <i>Frontiers in Immunology</i> , 2020, 11, 19.	2.2	6
5	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34); DEK-NUP214 shows a favourable outcome when performed in first complete remission. <i>British Journal of Haematology</i> , 2020, 189, 920-925.	1.2	16
6	Computational Analysis of HLA-presentation of Non-synonymous Recipient Mismatches Indicates Effect on the Risk of Chronic Graft-vs.-Host Disease After Allogeneic HSCT. <i>Frontiers in Immunology</i> , 2019, 10, 1625.	2.2	20
7	Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 522-528.	2.0	48
8	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	2.0	30
9	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 683-691.	1.3	13
10	Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Philadelphia negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 778-785.	2.0	21
11	Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT. <i>Cancer</i> , 2018, 124, 2523-2533.	2.0	18
12	Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 256-265.	1.7	18
13	Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. <i>Transfusion</i> , 2018, 58, 1973-1979.	0.8	8
14	A randomized study of cyclosporine and methotrexate with or without methylprednisolone for the prevention of graft-versus-host disease: Improved long-term survival with triple prophylaxis. <i>Cancer</i> , 2018, 124, 727-733.	2.0	6
15	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. <i>American Journal of Hematology</i> , 2018, 93, 1236-1244.	2.0	40
16	Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 1142-1152.	2.0	91
17	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 1753-1762.	0.6	278
18	Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Cancer</i> , 2017, 123, 2671-2679.	2.0	37

#	ARTICLE	IF	CITATIONS
19	Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2017, 102, 139-149.	1.7	88
20	Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. <i>Lancet Haematology</i> , 2017, 4, e293-e301.	2.2	83
21	Genetic polymorphism related to monocyte-macrophage function is associated with graft-versus-host disease. <i>Scientific Reports</i> , 2017, 7, 15666.	1.6	22
22	Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. <i>Blood Advances</i> , 2017, 1, 477-485.	2.5	76
23	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. <i>Haematologica</i> , 2016, 101, 248-255.	1.7	19
24	Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2016, 9, 79.	6.9	42
25	Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>European Journal of Haematology</i> , 2016, 96, 90-97.	1.1	16
26	Unmanipulated haploidentical versus matched unrelated donor allogeneic stem cell transplantation in adult patients with acute myelogenous leukemia in first remission: a retrospective pair-matched comparative study of the Beijing approach with the EBMT database. <i>Haematologica</i> , 2016, 101, e352-e354.	1.7	49
27	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2016, 128, 3499-3499.	0.6	2
28	An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2016, 128, 628-628.	0.6	1
29	Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP). <i>Blood</i> , 2016, 128, 4701-4701.	0.6	0
30	Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Transplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT. <i>Blood</i> , 2016, 128, 4643-4643.	0.6	0
31	Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 2279-2279.	0.6	1
32	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	0.6	0
33	Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2016, 128, 522-522.	0.6	0
34	Impact of FAB Classification on Predicting Outcome in Acute Myeloid Leukemia, Not Otherwise Specified, Patients Undergoing Allogeneic Stem Cell Transplantation in CR1: An Analysis of 1690 Patients from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 2899-2899.	0.6	5
35	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) with Complex Karyotypes (CK): A Retrospective Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) and MD Anderson Cancer Center (MDACC). <i>Blood</i> , 2016, 128, 3479-3479.	0.6	0
36	Center Characteristics and Procedure-Related Factors Have an Impact on Outcomes of Allogeneic Transplantation for Patients with CLL: A Retrospective Analysis from the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4663-4663.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Use of First or Second Generation TKI for CML after Allogeneic Stem Cell Transplantation: a Study By the CMWP of the EBMT. <i>Blood</i> , 2016, 128, 4685-4685.	0.6	2
38	The Use of Anti-Thymocyte Globulin Is Associated with Increased Chance of Survival Free from Relapse and Graft-Versus-Host Disease after Allogeneic Peripheral Blood Stem Cell Transplantation for Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 666-666.	0.6	0
39	A Randomized Study of Cyclosporine and Methotrexate with or without Methylprednisolone for the Prevention of Graft-Versus-Host Disease: Improved Long-Term Survival with the Triple Prophylaxis. <i>Blood</i> , 2016, 128, 2241-2241.	0.6	3
40	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. <i>Blood</i> , 2015, 126, 2062-2069.	0.6	93
41	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	1.2	80
42	Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 years old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , 2015, 90, 719-724.	2.0	18
43	Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. <i>Lancet Haematology</i> , 2015, 2, e384-e392.	2.2	46
44	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 400-408.	1.7	50
45	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Haematologica</i> , 2015, 100, 392-399.	1.7	139
46	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 4364-4364.	0.6	0
47	Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. <i>Blood</i> , 2015, 126, 1958-1958.	0.6	0
48	Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients. <i>Frontiers in Immunology</i> , 2014, 5, 405.	2.2	47
49	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-Up of a Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 135-138.	2.0	58
50	Outcome of Allogeneic Stem Cell Transplantation for Patients Transformed to Myelodysplastic Syndrome or Leukemia from Severe Aplastic Anemia: A Report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1446-1450.	2.0	7
51	Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. <i>Haematologica</i> , 2014, 99, 1582-1590.	1.7	36
52	Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers. <i>Blood</i> , 2014, 124, 2554-2554.	0.6	7
53	Reduced Intensity Vs. Standard Conditioning Followed By Allogeneic Stem Cell Transplantation for Patients with MDS or Secondary AML: A Prospective, Randomized Phase III Study of the Chronic Malignancies Working Party of the EBMT (RICMAC-Trial). <i>Blood</i> , 2014, 124, 320-320.	0.6	5
54	Allogeneic Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome (MDS) Patients at Lower Risk According to International Prognostic Scoring System (IPSS) : A Retrospective Study on Behalf of the CMWP of the EBMT. <i>Blood</i> , 2014, 124, 2530-2530.	0.6	0

#	ARTICLE	IF	CITATIONS
55	The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. <i>Blood</i> , 2014, 124, 681-681.	0.6	0
56	Allogeneic HCT in Patients with 17p-CLL: Results of a Non-Interventional Study of the EBMT & Eric. <i>Blood</i> , 2014, 124, 1224-1224.	0.6	0
57	Contrasting Factors Determine the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukaemia (AML): a Survey from the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2014, 124, 3945-3945.	0.6	0
58	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 1230-1230.	0.6	1
59	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning. a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2014, 124, 1216-1216.	0.6	0
60	Thiotepa-Based Vs TBI-Based Myeloablative Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myeloid Leukemia (AML) In First Complete Remission (CR1): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013, 122, 2123-2123.	0.6	1
61	Treosulfan Based Conditioning Prior To Allogeneic Stem Cell Transplantation (HSCT) For Acute Myelogenous Leukemia (AML): A Retrospective Analysis From The ALWP Of The EBMT. <i>Blood</i> , 2013, 122, 545-545.	0.6	3
62	Reduced Intensity Allogeneic Stem Cell Transplant In Patients With Multiple Myeloma: A Comparison Of Planned Autologous-Reduced Intensity Allogeneic Stem Cell Transplant (Auto-Allo) and Reduced Intensity Allogeneic Stem Cell Transplant (RIC) As Upfront Transplant In Patients With Multiple Myeloma, An EBMT Analysis. <i>Blood</i> , 2013, 122, 920-920.	0.6	2
63	Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT. <i>Blood</i> , 2013, 122, 542-542.	0.6	5
64	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. <i>Blood</i> , 2013, 122, 2092-2092.	0.6	0
65	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients â€” A Report From The Acute Leukemia Working Party Of EBMT. <i>Blood</i> , 2013, 122, 921-921.	0.6	0
66	Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 735-741.	0.8	251
67	Outcome and Prognostic Factors in Patients with Mantle Cell Lymphoma Relapsing After Autologous Stem Cell Transplantation: A Retrospective Study of the EBMT. <i>Blood</i> , 2012, 120, 474-474.	0.6	2
68	Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2012, 120, 1975-1975.	0.6	5
69	Allogeneic Stem Cell Transplantation for Multiple Myeloma: Possible Role in the Treatment.. <i>Blood</i> , 2012, 120, 3133-3133.	0.6	0
70	Randomized Trial On GvHD Prophylaxis with or without Anti T Cell Globulin ATG Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Updated Results and Evaluation of the European Group for Blood and Marrow Transplantation (EBMT) Risk Score.. <i>Blood</i> , 2012, 120, 3090-3090.	0.6	0
71	Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy.. <i>Blood</i> , 2012, 120, 3110-3110.	0.6	0
72	The Influence of Monosomal Karyotype On Survival in Patients with Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Survey On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2011, 118, 158-158.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Busulfan (Bu) Plus Cyclophosphamide (Cy) Versus TBI Plus Cy Conditioning for Allogeneic Stem Cell Transplantation (alloSCT) From Matched Unrelated Donors (MUD) In Adult Patients with AML in First Relapse: A Survey From the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2011, 118, 161-161.	0.6	1
74	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT. <i>Blood</i> , 2011, 118, 4107-4107.	0.6	0
75	Improved Survival with Ursodeoxycholic Acid Prophylaxis in Allogeneic Stem Cell Transplantation: Long-Term Follow-up of a Randomized Study of the Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 2011, 118, 488-488.	0.6	0
76	Prognostic Pre-Transplant Factors in Myelodysplastic Syndromes Primarily Treated by Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study on Behalf of the MDS Subcommittee of the Chronic Leukaemia Working Party of the EBMT. <i>Blood</i> , 2011, 118, 3014-3014.	0.6	0
77	Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors. <i>Blood</i> , 2010, 116, 1249-1249.	0.6	1
78	Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT. <i>Blood</i> , 2010, 116, 4558-4558.	0.6	1
79	Chronic Graft-Versus-Host Disease: Lessons From a Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation (HSCT) From Matched Unrelated Donors. <i>Blood</i> , 2010, 116, 212-212.	0.6	0
80	Monosomal Karyotype Predicts Poor Outcome for MDS/sAML Patients with Chromosome 7 Abnormalities After Allogeneic Stem Cell Transplantation for MDS/sAML. A Study of the MDS Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2009, 114, 293-293.	0.6	16
81	Tandem Autologous (ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT. <i>Blood</i> , 2009, 114, 52-52.	0.6	15
82	Comparison of Outcomes After Allogeneic HSCT for Adult Patients with AML in Remission Using in the Conditioning Regimen Either I.V. Busulfex (BU) Plus Cyclophosphamide (Cy) or TBI Plus Cy: An-ALWP-EBMT Survey. <i>Blood</i> , 2009, 114, 195-195.	0.6	2
83	T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective EBMT Analysis. <i>Blood</i> , 2009, 114, 2307-2307.	0.6	4
84	A Randomized Prospective Multicenter Phase III Trial Comparing Standard GvHD Prophylaxis with Cyclosporine and Methotrexate with Additional Pretransplant ATG Fresenius (ATG-F) in Allogeneic Stem Cell Transplantation from Matched Unrelated Donors. <i>Blood</i> , 2008, 112, 57-57.	0.6	2
85	Outcome after Allogeneic Stem Cell Transplantation for Adult Acute Myeloid Leukaemia Patients Exhibiting Isolated or Associated Trisomy 8 Chromosomal Abnormality: A Survey on Behalf of the Acute Leukemia Working Party (ALWP) of the EBMT. <i>Blood</i> , 2008, 112, 1129-1129.	0.6	4
86	Reduced Toxicity Conditioning with Treosulfan and Fludarabine in Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: Results of an International Prospective Phase II Trial. <i>Blood</i> , 2008, 112, 3274-3274.	0.6	7
87	Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: A Retrospective EBMT Analysis. <i>Blood</i> , 2007, 110, 47-47.	0.6	5
88	Adaptation of Coagulation and Fibrinolysis in Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2007, 110, 3023-3023.	0.6	0
89	Impact of Serum EBV-qPCR Positivity on the Outcome of Allogeneic Stem Cell Transplantation: A Retrospective Study of 406 Patients. <i>Blood</i> , 2005, 106, 3233-3233.	0.6	0
90	Human herpesvirus 6 antigenaemia in allogeneic stem cell transplant recipients: impact on clinical course and association with other beta-herpesviruses. <i>British Journal of Haematology</i> , 2004, 126, 690-696.	1.2	38

#	ARTICLE	IF	CITATIONS
91	EBV DNAemia after Allogeneic Stem Cell Transplantation (SCT): A Prospective Study in 131 High Risk Patients.. Blood, 2004, 104, 2242-2242.	0.6	0
92	Quality of life and factors related to perceived satisfaction with quality of life after allogeneic bone marrow transplantation. Annals of Hematology, 2001, 80, 137-143.	0.8	96
93	Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood, 2000, 96, 2391-2398.	0.6	94
94	Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood, 2000, 96, 2391-2398.	0.6	0
95	Prognostic Value of Metaphase-Fluorescence In Situ Hybridization in Follow-up of Patients With Acute Myeloid Leukemia in Remission. Blood, 1997, 89, 3330-3334.	0.6	17
96	Loss of protective immunity to polio, diphtheria and <i>Haemophilus influenzae</i> type b after allogeneic bone marrow transplantation. Apmis, 1996, 104, 383-388.	0.9	58
97	Overgrowth of <i>Enterococcus faecium</i> in the Feces of Patients with Hematologic Malignancies. Clinical Infectious Diseases, 1996, 23, 694-697.	2.9	33
98	An Outbreak of Invasive Aspergillosis in a Haematologic Unit. Scandinavian Journal of Infectious Diseases, 1987, 19, 347-351.	1.5	45